Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus PREVACID 24 HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus PREVACID 24 HR.
DEXILANT vs PREVACID 24 HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
15 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor